Home » Healthcare » Pharmaceuticals » Amyotrophic Lateral Sclerosis (ALS) Treatment Market

Amyotrophic Lateral Sclerosis (ALS) Treatment Market By Drug Type (Riluzole, Edaravone) – Growth, Share, Opportunities & Competitive Analysis, 2015 – 2025

Price: $4999

Published: | Report ID: 12675 | Report Format : PDF

Market Insights

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a neurological disease that causes the death of nerve cells that control voluntary muscles. Factors such as the increase in the incidence of ALS, a strong pipeline molecule, favorable reimbursement policies in some countries, and the expected launch of newer medications would drive the growth of the ALS treatment market globally.

The report titled “Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025” offers strategic insights into the overall ALS treatment market along with the market size and estimates for the duration of 2015–2025. The research study includes a thorough examination of market segments based on drug type (Riluzole, Edaravone, and Others) and geographical region.

Geographically, the global ALS treatment market is studied for the following regional markets:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • U.K.
    • Russia
    • Rest of Europe
  • Asia-Pacific
    • India
    • China
    • Japan
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East and Africa

The market size and forecast for these regional and country-level markets are presented in this study for the period 2015–2025. Market growth rates for the forecast period 2017–2025 are also included in this report, considering 2016 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for a better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges, opportunities, and pipeline analysis assists the readers in understanding the ongoing trends in the global ALS treatment market. Tools such as key player market positioning and appealing investment propositions provide readers with insights into the global ALS treatment market’s competitive scenario. This report concludes with a company profiles section that highlights major information about the key players engaged in the global ALS treatment market. In-depth competitive environment analysis and historical year (2015) market size data are also provided in the report.

Thus, the research study provides a holistic view of the global ALS treatment market, offering market size and estimates for the period from 2015 to 2025, keeping in mind the above-mentioned factors.

Based on drug type, the global amyotrophic lateral sclerosis (ALS) treatment market is segmented as follows:

  • Riluzole
  • Edaravone
  • Other

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease or Maladie de Charcot, is a neurological disease that causes nerve cells to gradually break down and die. According to the Centers for Disease Control and Prevention (CDC), 14,000 to 15,000 Americans had ALS in 2016. Factors such as increasing treatment awareness, strong pipeline molecules, a rising geriatric population, and the recent approval of new treatment medications are expected to drive the growth of the ALS treatment market globally. Currently, there is no cure for ALS; however, treatments are available to control symptoms and prevent unnecessary complications. The U.S. Food and Drug Administration (FDA) has approved only two drugs for the treatment of ALS, which include Riluzole (Rilutek) and Edaravone (Radicava).

Other medications are prescribed to control ALS symptoms, such as muscle cramps and spasms, spasticity, constipation, fatigue, excessive salivation, excessive phlegm, pain, depression, and sleep problems. It is studied that in the base year 2016, Riluzole (Rilutek) was a major revenue-generating segment due to high compliance because it is the only medication used in the treatment of ALS and works by reducing levels of a chemical messenger in the brain (glutamate) that is often present at higher levels in people with ALS.

The 2013 patent expiry of Rilutek has negatively impacted the growth of the ALS treatment market. On the other hand, the recently approved Radicava is expected to show the highest growth rate during the forecast period due to its applicability and higher cost, which are expected to drive market growth during the forecast period. Moreover, the expected launch of ALS treatment molecules such as AB-1010 (masitinib), Methycobal (mecobalamin), Arimoclomol, and CK-2017-357 (CK-357, tirasemtiv) would assist market growth during the forecast period.

For the purpose of this study, the global amyotrophic lateral sclerosis (ALS) treatment market is categorized into three segments:

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

It is observed that, in the base year 2016, North America dominated the ALS treatment market in terms of revenue due to factors such as an upsurge in funding by government agencies and private organizations in the healthcare system, an increase in the prevalence of neurological diseases, and higher treatment awareness that assisted market growth in North America. According to the National ALS Registry, in 2016, more than 12,000 people in the United States had a definite diagnosis of ALS, with a prevalence of 3.9 cases per 100,000 persons in the U.S. general population. According to the National Organization for Rare Disorders (NORD), ALS is a rare disorder; approximately 5,000 new cases are diagnosed each year in the United States.

Even though Riluzole is expensive, insurance policies such as Medicare and the National Organization for Rare Diseases also cover Riluzole. Furthermore, the Covis Patient Assistance Program helps U.S. citizens or residents who don’t have a health care plan or have been denied coverage for treatment, which is further driving the market’s growth in North America. It is estimated that Asia Pacific will show the highest growth rate during the forecast period due to increasing healthcare awareness, increasing partnerships of key players such as Biogen, Avicena, Mitsubishi Tanabe, and Sanofi with local manufacturers, populous countries, and developing economic conditions, which will fuel the ALS treatment market’s growth.

Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary
2.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Snapshot
2.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market, Drug Type
2.3 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share, by Geography, 2016 (Value %)

Chapter 3 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Analysis
3.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Overview
3.2 Market Dynamics
3.2.1 Market Drivers
3.2.2 Challenges
3.2.3 Opportunities
3.3 Pipeline Analysis of Amyotrophic Lateral Sclerosis (ALS) Treatment Market
3.4 Epidemiology of Amyotrophic lateral sclerosis (ALS)
3.5 Attractive Investment Proposition
3.6 Competitive Landscape of Key Players in Amyotrophic Lateral Sclerosis (ALS) Treatment Market

Chapter 4 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Drug Type
4.1 Overview
4.2 Top 3 Countries
4.3 Riluzole
4.4 Edaravone
4.5 Other

Chapter 5 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market, By Geography
5.1 Preface
5.2 North America (U.S. & Canada)
5.2.1 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Drug Type, 2015- 2025 (US$)
5.2.2 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Country, 2015- 2025 (US$)
5.3 Europe (U.K., Germany & Rest of Europe)
5.3.1 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Drug Type, 2015- 2025 (US$)
5.3.2 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Country, 2015- 2025 (US$)
5.4 Asia Pacific (China, Japan and Rest of APAC)
5.4.1 Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Drug Type, 2015- 2025 (US$)
5.4.1 Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Country, 2015- 2025 (US$)
5.5 Latin America (Brazil, Mexico and Rest of LATAM)
5.5.1 Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Drug Type, 2015- 2025 (US$)
5.5.2 Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Country, 2015- 2025 (US$)
5.6 Middle East and Africa (GCC and Rest of MEA)
5.6.1 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Drug Type, 2015- 2025 (US$)
5.6.2 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Country, 2015- 2025 (US$)

Chapter 6 Company Profiles
6.1 AB Science
6.2 Avicena Group
6.3 Biogen
6.4 BrainStorm Therapeutics
6.5 Covis Pharmaceutical Inc.
6.6 Cytokinetics Inc.
6.7 Eisai Co. Ltd.
6.8 GlaxoSmithKline plc.
6.9 Ionis Pharmaceuticals, Inc.
6.10 Mitsubishi Tanabe Pharma Corp.
6.11 Neuralstem Inc.
6.12 Neuraltus Pharmaceuticals Inc.
6.13 Newron Pharmaceuticals S.p.A.
6.14 Pharnext SAS
6.15 Q-Therapeutics Inc.

List of Figures

FIG. 1 Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Research Methodology
FIG. 2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Drug Type, 2016 (US$ Mn)
FIG. 3 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share, by Geography, 2016 (Value %)
FIG. 4 Attractive Investment Proposition: Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Geography, 2016
FIG. 5 Global Riluzole Market, 2015 – 2025 (US$ Mn)
FIG. 6 Global Edaravone Market, 2015 – 2025 (US$ Mn)
FIG. 7 Global Other ALS Treatment Drugs Market, 2015 – 2025 (US$ Mn)

List of Tables

TABLE 1 Market Positioning of Key Players in Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market
TABLE 2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Drug Type, 2015 – 2025 (US$ Mn)
TABLE 3 Top 3 Countries in Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market, 2015 – 2025 (US$ Mn)
TABLE 4 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Geography, 2015 – 2025 (US$ Mn)
TABLE 5 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Drug Type, 2015-2025 (US$ Mn)
TABLE 6 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 7 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Drug Type, 2015-2025 (US$ Mn)
TABLE 8 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 9 Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Drug Type, 2015-2025 (US$ Mn)
TABLE 10 Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 11 Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Drug Type, 2015-2025 (US$ Mn)
TABLE 12 Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 13 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Drug Type, 2015-2025 (US$ Mn)
TABLE 14 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 15 AB Science: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 16 Avicena Group: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 17 Biogen: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 18 BrainStorm Therapeutics: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 19 Covis Pharmaceutical Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 20 Cytokinetics Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 21 Eisai Co. Ltd.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 22 GlaxoSmithKline plc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 23 Ionis Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 24 Mitsubishi Tanabe Pharma Corp.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 25 Neuralstem Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 26 Neuraltus Pharmaceuticals Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 27 Newron Pharmaceuticals S.p.A.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 28 Nutra Pharma Corp.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 29 Pharnext SAS: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 30 Q-Therapeutics Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)

Frequently Asked Question:

What is the size of Amyotrophic Lateral Sclerosis Treatment Market?

The market for Amyotrophic Lateral Sclerosis Treatment Market is expected to reach USD$ 306.6 Mn in 2025.

What is the Amyotrophic Lateral Sclerosis Treatment Market CAGR?

The Amyotrophic Lateral Sclerosis Treatment Market is expected to see significant CAGR growth over the coming years, at 21.1%.

What is the Forecast period considered for Amyotrophic Lateral Sclerosis Treatment Market?

The report is forecasted from 2015-2025.

What is the base year considered for Amyotrophic Lateral Sclerosis Treatment Market?

The base year of this report is 2014.

Who are the major players in this market?

AB Science,Avicena Group,Biogen,BrainStorm Therapeutics,Covis Pharmaceutical Inc.are some of the major players in the global market.

Inulin Market

Published:
Report ID: 11192

Drug Discovery Market

Published:
Report ID: 38270

Neurotrophic Keratitis Treatment Market

Published:
Report ID: 33425

Japan’s Pharmacy Automation Market

Published:
Report ID: 37511

Sterile Active Pharmaceutical Ingredient Market

Published:
Report ID: 37476

Organ Preservation Solutions Market

Published:
Report ID: 37472

Middle East and Africa Veterinary Vaccines Market

Published:
Report ID: 37309

Asia Pacific Stem Cell Therapy Market

Published:
Report ID: 37280

US Active Pharmaceutical Ingredient (API) Market

Published:
Report ID: 37221

Cancer Supportive Care Market

Published:
Report ID: 1901

Middle East and Africa Radiopharmaceuticals Market

Published:
Report ID: 37164

Temperature Controlled Pharma Packaging Solutions Market

Published:
Report ID: 20599

Purchase Options

$2999
Delivery Format: Excel.
$4999
Designed for the individual purchaser.
$6999
Users located at a single corporate site or regional office.
$7999
Allowed for unlimited sharing globally within one company.
Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207


support

24/7 Research Support


sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN